8-K - Seer, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

PTAB upheld 23 claims of Seer Inc.'s U.S. Patent No. 11,435,360, including five challenged claims, validating the company's nanoparticle protein enrichment technology for the Proteograph platform.

Key Takeaways

1PTAB issued Final Written Decision on March 23, 2026, upholding claims 2, 3, 7, 23, 24 of the ‘360 patent.

223 claims total remain valid and enforceable, including 5 upheld and 18 unchallenged.

3Petitioners PreOmics GmbH and Biognosys AG (Bruker subsidiaries) challenged claims 1-4, 6, 7, 17, 22-25; claims 1, 4, 6, 22, 25 found unpatentable.

4‘360 Patent covers methods using engineered nano- and microparticles for protein coronas in proteomic analysis, exclusively licensed to Seer.

5Upheld claims relate to protein detection depth, dynamic range, and particle aspects supporting Proteograph Product Suite.

6Appeal notice must be filed by May 25, 2026 if pursued by either party.

Current Report Details

Event Type

Other Event

Exhibits Only

Disclosure

Voluntary

Variant

8-K

Items Reported

8.01

| Other Events. | |---|---| On March 30, 2026, Seer, Inc. announced that the Patent Trial and Appeal Board (“PTAB”) of the U.S. Patent and Trademark Office issu

Other Event

9.01

| Financial Statements and Exhibits. | |---|---| | Exhibit No. | | Description | |---|---|---| | 99.1 | | Press Release dated March 30, 2026, titled “Seer's Par

Exhibits Only

Source Document

Exhibits (2)

8-K

99.1

EX-99.1